Brookline Capital Markets initiated coverage of Medicus Pharma (NASDAQ:MDCX) with a buy rating, citing the potential of its ...

Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in HorsesTORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ ...

Medicus Pharma Ltd. has announced that its Investigational New Animal Drug for a dissolvable Doxorubicin-containing microneedle array (D-MNA) has received Minor Use in Major Species Designation ...

Medicus Pharma Ltd (MDCX) has received a new Buy rating, initiated by Brookline Capital Markets analyst, Kumaraguru Raja.Don't Miss Our ...

CHEB.WSChenghe Acquisition II Co. Chenghe Acquisition II Co. SBXD.WSSilverBox Corp IV WT EXP 081929 SilverBox Corp IV WT EXP 081929 AAM.WSAA Mission Acquisition Corp. WT EXP 080131 AA Mission ...

Bucking the trend, a number of Philadelphia-area life sciences companies raised more than $100 million in private equity ...

TORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal ...

Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing D-MNA, a doxorubicin tip loaded dissolvable microarray ...